13F reference period
Q2 2026
Security Snapshot
Alto Neuroscience, Inc. - Common Stock (ANRO) Institutional Ownership
CUSIP: 02157Q109
13F Institutional Holders and Ownership History from Q1 2024 to Q3 2026
Institutions Reporting
114
Shares (Excl. Options)
29.47M
Full value: 29,470,567 · shares · 30 Jun 2026Price
$26.39
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ANRO on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 29,470,567
- Total 13F value
- $777,643,740
- Portfolio coverage rank
- 0%
- Share change
- +2,636,252
- Value change
- +$73,485,814
- Number of holders
- 114
- Shares outstanding
- 39,245,179
- SEC-reported price per share
- $22.09
- Insider filing price
- $22.09
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ANRO - Alto Neuroscience, Inc. - Common Stock is tracked under CUSIP 02157Q109.
- 114 institutions reported positions in Q2 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 110 to 114 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$602.48M
Full value: $602,479,913 · USD · 31 Mar 2026.$777.64M
Full value: $777,643,740 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 114 institutions filings for Q2 2026.
Security key
02157Q109
13F reference period
Q2 2026
13F holders
114
13D/G owners
11
CIK / CUSIP context first
Open Q2 2026 holders
ANRO full holder history
Alto Neuroscience, Inc. SEC filings
Alto Neuroscience, Inc. company facts
Alto Neuroscience, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 02157Q109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
ANRO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% | 0% | $107,341,473 | +$23,818,169 | 4,176,711 | +29% | Perceptive Advisors LLC | 30 Jun 2026 |
| Commodore Capital LP | 9.9% | 0% | $77,791,742 | +$7,426,527 | 3,588,180 | +11% | Commodore Capital LP | 31 Mar 2026 |
| EcoR1 Capital, LLC | 5.8% | $58,885,740 | 2,232,000 | EcoR1 Capital, LLC | 13 Jul 2026 | |||
| Sirenia Capital Management LP | 6.2% | -21% | $57,042,898 | -$9,560,888 | 2,219,568 | -14% | Sirenia Capital Management LP | 30 Jun 2026 |
| BlackRock, Inc. | 6% | +195% | $55,535,274 | +$40,720,905 | 2,104,406 | +275% | BlackRock, Inc. | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $50,296,660 | 1,970,108 | Vanguard Capital Management | 30 Sep 2026 | |||
| ARMISTICE CAPITAL, LLC | 4.9% | -16% | $23,546,880 | -$981,120 | 1,536,000 | -4% | Armistice Capital, LLC | 31 Dec 2025 |
| FMR LLC | 4.7% | $2,885,445 | 1,265,546 | FMR LLC | 31 Dec 2024 | |||
| Point72 Asset Management, L.P. | 3.7% | -58% | $25,384,353 | -$35,845,929 | 1,170,865 | -59% | Steven A. Cohen | 31 Mar 2026 |
| K2 HealthVentures Equity Trust LLC | 2.4% | -53% | $13,018,418 | -$13,676,190 | 788,995 | -51% | K2 HealthVentures Equity Trust LLC | 31 Dec 2025 |
| Vestal Point Capital, LP | 2.2% | -61% | $20,174,500 | -$32,872,228 | 785,000 | -62% | Vestal Point Capital, LP | 30 Jun 2026 |
As of 30 Jun 2026,
114
institutional investors reported holding
shares of
Alto Neuroscience, Inc. - Common Stock (ANRO).
This represents
75%
of the company’s total
outstanding shares.
29.47M
Full value: 29,470,567 · shares · 30 Jun 202639.25M
Full value: 39,245,179 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
66%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Alpha Wave Global, LP | 9.4% | 3,707,757 | 0% | 1.6% | $97,847,707 |
| Commodore Capital LP | 6.9% | 2,723,196 | 0% | 4.3% | $71,865,142 |
| BlackRock, Inc. | 5.4% | 2,121,009 | +218% | 0% | $55,973,428 |
| PERCEPTIVE ADVISORS LLC | 4.1% | 1,609,893 | -20% | 0.66% | $42,485,076 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.1% | 1,600,000 | +316% | 0.06% | $42,224,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 1,389,477 | +15% | 0% | $36,668,298 |
| Spruce Street Capital LP | 3.4% | 1,353,047 | +2.1% | 7% | $35,706,910 |
| Vivo Capital, LLC | 3.1% | 1,208,858 | +17% | 2.9% | $31,901,763 |
| FRANKLIN RESOURCES INC | 2.6% | 1,013,307 | -8% | 0.01% | $26,741,172 |
| ARMISTICE CAPITAL, LLC | 2.2% | 864,000 | -5.3% | 0.63% | $22,800,960 |
| Affinity Asset Advisors, LLC | 2.2% | 850,000 | +70% | 1.1% | $22,431,500 |
| Vestal Point Capital, LP | 2% | 785,000 | -62% | 0.48% | $20,716,150 |
| STATE STREET CORP | 1.7% | 685,945 | +244% | 0% | $18,102,089 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 678,199 | +132% | 0% | $17,902,152 |
| 72 Investment Holdings, LLC | 1.7% | 667,778 | 0% | 35% | $17,622,661 |
| NORTHERN TRUST CORP | 1.6% | 632,701 | +34% | 0% | $16,696,980 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 558,320 | -32% | 0.01% | $14,734,065 |
| Point72 Asset Management, L.P. | 1.3% | 502,950 | -0.03% | 0.02% | $13,272,851 |
| Venrock Adviser, LLC | 1.3% | 500,000 | 0% | 0.4% | $13,195,000 |
| Integral Health Asset Management, LLC | 1.3% | 500,000 | 0% | 0.54% | $13,195,000 |
| Driehaus Capital Management LLC | 1.2% | 487,576 | +0.17% | 0.07% | $12,867,131 |
| Parkman Healthcare Partners LLC | 1.1% | 429,035 | 1.2% | $11,322,234 | |
| Ikarian Capital, LLC | 1% | 407,338 | -21% | 1.8% | $10,749,651 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.91% | 358,279 | -3.5% | 0% | $9,456,000 |
| ORBIMED ADVISORS LLC | 0.66% | 257,852 | +54% | 0.13% | $6,804,714 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Headline period
Q2 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 230,380 | $5,859,294 | +$2,441,607 | $25.53 | 18 |
| 2026 Q2 | 29,470,567 | $777,643,740 | +$73,485,814 | $26.39 | 114 |
| 2026 Q1 | 26,830,701 | $602,479,913 | +$54,953,807 | $22.48 | 110 |
| 2025 Q4 | 24,487,002 | $435,860,904 | +$135,656,607 | $17.80 | 96 |
| 2025 Q3 | 16,755,091 | $67,358,617 | -$1,672,076 | $4.02 | 74 |
| 2025 Q2 | 17,296,212 | $38,050,471 | -$7,942,231 | $2.20 | 78 |
| 2025 Q1 | 20,845,367 | $45,026,701 | -$4,167,716 | $2.16 | 83 |
| 2024 Q4 | 22,530,140 | $95,292,066 | -$45,543,045 | $4.23 | 77 |
| 2024 Q3 | 22,939,574 | $265,498,730 | +$37,026,413 | $11.44 | 75 |
| 2024 Q2 | 18,600,674 | $198,841,035 | +$25,849,471 | $10.69 | 58 |
| 2024 Q1 | 15,971,812 | $245,167,778 | +$245,167,778 | $15.35 | 52 |